About US
Contact us
-
Plagued by production issues, Pfizer aims to shift EpiPen work to Mylan-Upjohn mergerMylan’s EpiPen has had a troubled few years—to say the least—with federal prosecutors knocking at the door and shortages plaguing production. Now, with Mylan and Pfizer's generic business Upjohn work2019/7/31
-
Pfizer points to newer meds—including Ibrance—as post-Upjohn cash enginesOn the heels of news it would spin off its generics wing, Pfizer is looking at a much different future without that $2.8 billion cash engine. But CEO Albert Bourla has a message for investors concern2019/7/30
-
'Autonomous,' yes, but not for sale: Novartis won't sell Sandoz, CEO Vas Narasimhan saysNovartis granting Sandoz independence within the company sounds a lot like what Pfizer did with its own generics business before it struck a deal to merge the unit with Mylan. But to hear Novartis CE2019/7/30
-
Sanofi takes $2B hemophilia write-down as Roche's Hemlibra brings the heatIt’s been just over 16 months since Sanofi closed its $11.6billion buyout of hemophilia specialist Bioverativ. But the company is already revising its sales projections for one of Bioverativ’s key pr2019/7/29
-
Sanofi dumps Zynquista collab following phase 3 failures, but Lexicon claps backSanofi could use a boost from new launches, but it apparently doesn't think it'll get what it needs from diabetes hopeful Zynquista. It's calling it quits on the drug, which theFDA rejected for Type2019/7/29
-
Mylan CEO Bresch set to exit after years of controversy—and one last big dealDuring Mylan CEO Heather Bresch's 28-year stint there, the company has utterly transformed into a generics giant—and courted controversy along the way. And now, Bresch says she's stepping aside to cl2019/7/26
-
Deja vu? Pharma ad tax deduction faces threats—again—in Congress, on the trailPharma's advertising tax deduction is back on the chopping block, both in Congress and on the 2020 campaign trail. Last week, as a Senate drug-pricing reform bill made its way through the Finance Com2019/7/26
-
Pfizer's big split is finally here, thanks to a giant generics merger with MylanLooks like consumer health isn’t the only franchise Pfizer is looking to shed. In a payoff for years of split-up talk, thepharma giant's got hive-off plans for its generics business, too. And those p2019/7/25
-
Red flag upgrade for Pfizer: FDA limits Xeljanz in colitis, slaps black box on labelFor Pfizer’s blockbuster immunology drug Xeljanz, an FDA safety communication has now turned into a boxed warning. And forget the drug's approval as a first-line ulcerative colitis treatment, at leas2019/7/25
-
Vertex's planned CEO handoff could signal stagnant growth to come: analystSuccession planning is usually nothing to balk at—in fact, it’s considered responsible governance, particularly at a fast-growing company like Vertex Pharmaceuticals. But could Vertex'splan to move C2019/7/24